JP2004210767A5 - - Google Patents

Download PDF

Info

Publication number
JP2004210767A5
JP2004210767A5 JP2003408898A JP2003408898A JP2004210767A5 JP 2004210767 A5 JP2004210767 A5 JP 2004210767A5 JP 2003408898 A JP2003408898 A JP 2003408898A JP 2003408898 A JP2003408898 A JP 2003408898A JP 2004210767 A5 JP2004210767 A5 JP 2004210767A5
Authority
JP
Japan
Prior art keywords
isobologram
shows
compounds
concave form
synergy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003408898A
Other languages
English (en)
Japanese (ja)
Other versions
JP4149905B2 (ja
JP2004210767A (ja
Filing date
Publication date
Priority claimed from GBGB9615942.1A external-priority patent/GB9615942D0/en
Priority claimed from GBGB9705684.0A external-priority patent/GB9705684D0/en
Application filed filed Critical
Publication of JP2004210767A publication Critical patent/JP2004210767A/ja
Publication of JP2004210767A5 publication Critical patent/JP2004210767A5/ja
Application granted granted Critical
Publication of JP4149905B2 publication Critical patent/JP4149905B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2003408898A 1996-07-30 2003-12-08 サイクロスポリンaおよび40−o−(2−ヒドロキシエチル)−ラパマイシンを含む移植拒絶、自己免疫疾患または炎症性状態の処置用医薬組成物 Expired - Lifetime JP4149905B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9615942.1A GB9615942D0 (en) 1996-07-30 1996-07-30 Organic compounds
GBGB9705684.0A GB9705684D0 (en) 1997-03-18 1997-03-18 Organic compounds

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP50851398A Division JP3942641B2 (ja) 1996-07-30 1997-07-29 サイクロスポリンaおよび40―o―(2―ヒドロキシエチル)―ラパマイシンを含む移植拒絶、自己免疫疾患または炎症性状態の処置用医薬組成物

Publications (3)

Publication Number Publication Date
JP2004210767A JP2004210767A (ja) 2004-07-29
JP2004210767A5 true JP2004210767A5 (https=) 2005-05-26
JP4149905B2 JP4149905B2 (ja) 2008-09-17

Family

ID=26309775

Family Applications (2)

Application Number Title Priority Date Filing Date
JP50851398A Expired - Lifetime JP3942641B2 (ja) 1996-07-30 1997-07-29 サイクロスポリンaおよび40―o―(2―ヒドロキシエチル)―ラパマイシンを含む移植拒絶、自己免疫疾患または炎症性状態の処置用医薬組成物
JP2003408898A Expired - Lifetime JP4149905B2 (ja) 1996-07-30 2003-12-08 サイクロスポリンaおよび40−o−(2−ヒドロキシエチル)−ラパマイシンを含む移植拒絶、自己免疫疾患または炎症性状態の処置用医薬組成物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP50851398A Expired - Lifetime JP3942641B2 (ja) 1996-07-30 1997-07-29 サイクロスポリンaおよび40―o―(2―ヒドロキシエチル)―ラパマイシンを含む移植拒絶、自己免疫疾患または炎症性状態の処置用医薬組成物

Country Status (14)

Country Link
US (2) US6239124B1 (https=)
EP (2) EP1208847B8 (https=)
JP (2) JP3942641B2 (https=)
AT (2) ATE340586T1 (https=)
AU (1) AU730781B2 (https=)
CA (1) CA2261666C (https=)
CY (1) CY2391B1 (https=)
DE (2) DE69736750T2 (https=)
DK (2) DK1208847T3 (https=)
ES (2) ES2270948T3 (https=)
NZ (1) NZ333657A (https=)
PT (2) PT956034E (https=)
SI (1) SI1208847T1 (https=)
WO (1) WO1998004279A1 (https=)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE398448T1 (de) * 1993-09-28 2008-07-15 Scherer Gmbh R P Herstellung von weichgelatinekapseln
US5858401A (en) 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
PT956034E (pt) * 1996-07-30 2002-12-31 Novartis Ag Composicoes farmaceuticas para o tratamento da rejeicao de transplantes estados inflamatorios ou auto-imunes compreendendo ciclosporina a e 40-o-(2-hidroxietil)-rapamicina
US20030199425A1 (en) * 1997-06-27 2003-10-23 Desai Neil P. Compositions and methods for treatment of hyperplasia
US6890546B2 (en) 1998-09-24 2005-05-10 Abbott Laboratories Medical devices containing rapamycin analogs
US20030129215A1 (en) * 1998-09-24 2003-07-10 T-Ram, Inc. Medical devices containing rapamycin analogs
GB9825632D0 (en) * 1998-11-23 1999-01-13 Novartis Ag Organic compounds
GB9826882D0 (en) 1998-12-07 1999-01-27 Novartis Ag Organic compounds
US20020006901A1 (en) * 1999-02-05 2002-01-17 Aldo T. Iacono Use of aerosolized cyclosporine for prevention and treatment of pulmonary disease
DE60044717D1 (de) * 1999-05-10 2010-09-02 Paolo Brenner Kombination von immunsuppressiven substanzen zur behandlung oder vorbeugung von transplantat abstossungen
CA2427569C (en) * 2000-11-03 2010-07-27 Matrix Therapeutics Limited Selective glucocorticoid receptor agonists
US20020127263A1 (en) * 2001-02-27 2002-09-12 Wenda Carlyle Peroxisome proliferator-acitvated receptor gamma ligand eluting medical device
US8741378B1 (en) 2001-06-27 2014-06-03 Advanced Cardiovascular Systems, Inc. Methods of coating an implantable device
US20040137066A1 (en) * 2001-11-26 2004-07-15 Swaminathan Jayaraman Rationally designed therapeutic intravascular implant coating
US6641611B2 (en) * 2001-11-26 2003-11-04 Swaminathan Jayaraman Therapeutic coating for an intravascular implant
US20080145402A1 (en) * 2001-09-10 2008-06-19 Abbott Cardiovascular Systems Inc. Medical Devices Containing Rapamycin Analogs
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
IL160761A0 (en) * 2001-10-19 2004-08-31 Isotechnika Inc Novel cyclosporin analog microemulsion preconcentrates
JP2005514344A (ja) * 2001-10-25 2005-05-19 アセロジエニクス・インコーポレイテツド 移植拒絶治療のための化合物と方法
US6939376B2 (en) * 2001-11-05 2005-09-06 Sun Biomedical, Ltd. Drug-delivery endovascular stent and method for treating restenosis
US7682387B2 (en) 2002-04-24 2010-03-23 Biosensors International Group, Ltd. Drug-delivery endovascular stent and method for treating restenosis
US7109169B2 (en) * 2002-06-28 2006-09-19 Hobai Ion A Method for treating heart failure by inhibiting the sarcolemmal sodium/calcium exchange
CA2492153C (en) 2002-07-16 2012-05-08 Biotica Technology Limited Production of polyketide fkbp-ligand analogues
US20060171984A1 (en) * 2002-09-06 2006-08-03 Cromack Keith R Device having hydration inhibitor
DK1539157T3 (da) * 2002-09-18 2013-10-07 Univ Pennsylvania Fremgangsmåde til hæmning af choroidal neovaskularisering
US8202530B2 (en) * 2002-09-27 2012-06-19 Advanced Cardiovascular Systems, Inc. Biocompatible coatings for stents
AR043504A1 (es) * 2003-03-17 2005-08-03 Novartis Ag Composiciones farmaceuticas que comprenden rapamicina para el tratamiento de enfermedades inflamatorias
US7160867B2 (en) 2003-05-16 2007-01-09 Isotechnika, Inc. Rapamycin carbohydrate derivatives
WO2005020993A1 (en) 2003-08-29 2005-03-10 Lifecycle Pharma A/S Modified release compositions comprising tacrolimus
KR20060085246A (ko) 2003-09-18 2006-07-26 마커사이트, 인코포레이티드 경공막 전달
WO2006115509A2 (en) 2004-06-24 2006-11-02 Novartis Vaccines And Diagnostics Inc. Small molecule immunopotentiators and assays for their detection
US8709469B2 (en) 2004-06-30 2014-04-29 Abbott Cardiovascular Systems Inc. Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device
GB0417852D0 (en) 2004-08-11 2004-09-15 Biotica Tech Ltd Production of polyketides and other natural products
US8021849B2 (en) * 2004-11-05 2011-09-20 Siemens Healthcare Diagnostics Inc. Methods and kits for the determination of sirolimus in a sample
DK1848431T3 (en) 2005-02-09 2016-04-18 Santen Pharmaceutical Co Ltd LIQUID FORMULATIONS FOR TREATMENT OF DISEASES OR CONDITIONS
US8663639B2 (en) 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
WO2006089312A2 (en) * 2005-02-15 2006-08-24 Wyeth Orally bioavailable cci-779 tablet formulations
KR20070114753A (ko) * 2005-02-18 2007-12-04 아브락시스 바이오사이언스 인크. 치료제의 조합 및 투여 방식, 및 조합 요법
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
WO2006095173A2 (en) 2005-03-11 2006-09-14 Biotica Technology Limited Medical uses of 39-desmethoxyrapamycin and analogues thereof
GB0504994D0 (en) 2005-03-11 2005-04-20 Biotica Tech Ltd Novel compounds
AU2006227116A1 (en) * 2005-03-21 2006-09-28 Santen Pharmaceutical Co., Ltd. Drug delivery systems for treatment of diseases or conditions
AU2006235478B2 (en) * 2005-04-12 2011-07-21 Elan Pharma International Limited Nanoparticulate and controlled release compositions comprising cyclosporine
US7189582B2 (en) * 2005-04-27 2007-03-13 Dade Behring Inc. Compositions and methods for detection of sirolimus
US20100004738A1 (en) * 2005-04-29 2010-01-07 Atrium Medical Corporation Drug delivery coating for use with a medical device and methods of treating vascular injury
US20080020040A1 (en) * 2006-07-18 2008-01-24 Horizon Therapeutics, Inc. Unit dose form for administration of ibuprofen
US8067451B2 (en) 2006-07-18 2011-11-29 Horizon Pharma Usa, Inc. Methods and medicaments for administration of ibuprofen
US20080021078A1 (en) * 2006-07-18 2008-01-24 Horizon Therapeutics, Inc. Methods and medicaments for administration of ibuprofen
EP1919288A4 (en) * 2005-07-18 2009-12-16 Horizon Therapeutics Inc FAMOTIDINE- AND IBUPROGEN-BASED MEDICAMENTS AND THEIR ADMINISTRATION
KR20140093764A (ko) 2006-02-09 2014-07-28 산텐 세이야꾸 가부시키가이샤 안정한 제제와 그 제조 및 사용 방법
ES2563288T3 (es) 2006-03-23 2016-03-14 Santen Pharmaceutical Co., Ltd Rapamicina en dosis bajas para el tratamiento de enfermedades relacionadas con la permeabilidad vascular
US8067033B2 (en) 2007-11-30 2011-11-29 Horizon Pharma Usa, Inc. Stable compositions of famotidine and ibuprofen
US20100297224A1 (en) * 2006-08-31 2010-11-25 Horizon Therapeutics, Inc. NSAID Dose Unit Formulations with H2-Receptor Antagonists and Methods of Use
US8661630B2 (en) 2008-05-21 2014-03-04 Abbott Cardiovascular Systems Inc. Coating comprising an amorphous primer layer and a semi-crystalline reservoir layer
DE102008060549A1 (de) 2008-12-04 2010-06-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
MX2012011155A (es) 2010-03-29 2012-12-05 Abraxis Bioscience Llc Metodos para mejorar suministros de farmacos y efectividad de agentes terapeuticos.
EP3141245A1 (en) 2010-03-29 2017-03-15 Abraxis BioScience, LLC Methods of treating cancer
US8685433B2 (en) 2010-03-31 2014-04-01 Abbott Cardiovascular Systems Inc. Absorbable coating for implantable device
MX347225B (es) 2010-06-04 2017-04-19 Abraxis Bioscience Llc * Metodos de tratamiento contra el cancer pancreatico.
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
CA2825786A1 (en) * 2011-01-31 2012-08-09 Osaka University Externally-used drug for treating skin disorder and method for producing same
JP2014516075A (ja) 2011-06-06 2014-07-07 シェブロン フィリップス ケミカル カンパニー エルピー 癌治療のためのメタロセン化合物の使用
GB201122305D0 (en) 2011-12-23 2012-02-01 Biotica Tech Ltd Novel compound
US9220759B2 (en) 2012-02-23 2015-12-29 Abbott Cardiovascular Systems Inc. Treatment of diabetic patients with a drug eluting stent and adjunctive therapy
US9220584B2 (en) 2012-03-30 2015-12-29 Abbott Cardiovascular Systems Inc. Treatment of diabetic patients with a stent and locally administered adjunctive therapy
EP2705856A1 (en) 2012-09-07 2014-03-12 Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. Compounds for the treatment of neurodegenerative disorders
AU2014209141B2 (en) 2013-01-24 2018-05-10 Palvella Therapeutics, Inc. Compositions for transdermal delivery of mTOR inhibitors
SG11201602232UA (en) 2013-09-24 2016-04-28 Giner Inc System for gas treatment of a cell implant
WO2016033549A2 (en) 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
US20160361322A1 (en) 2015-06-15 2016-12-15 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
US20180321258A1 (en) * 2015-11-06 2018-11-08 The Trustees Of Columbia University In The City Of New York Exosomal Protein Profiling for Detection of Cardiac Transplant Rejection
AU2017361260B2 (en) 2016-11-15 2023-06-08 Giner, Inc. Percutaneous gas diffusion device suitable for use with a subcutaneous implant
US11559530B2 (en) 2016-11-28 2023-01-24 Lipocine Inc. Oral testosterone undecanoate therapy
EP3565520B1 (en) 2017-01-06 2026-02-25 Palvella Therapeutics, Inc. Anhydrous compositions of mtor inhibitors and methods of use
JP2020507632A (ja) 2017-02-10 2020-03-12 マウント タム セラピューティクス, インコーポレイテッドMount Tam Therapeutics, Inc. ラパマイシン類似体
CN110831656A (zh) 2017-05-04 2020-02-21 吉纳生命科学公司 稳健的可植入气体递送装置和方法、系统以及包括该装置的装置
US11000513B2 (en) 2018-07-02 2021-05-11 Palvella Therapeutics, Inc. Anhydrous compositions of mTOR inhibitors and methods of use
WO2020018974A1 (en) 2018-07-20 2020-01-23 Lipocine Inc. Liver disease

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4894366A (en) 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
US5100899A (en) 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
US5286730A (en) * 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory disease
US5286731A (en) 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory bowel disease
ATE138807T1 (de) 1992-03-27 1996-06-15 American Home Prod 29-demethoxyrapamycin zur induktion der immunosuppression
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
GB2278780B (en) 1993-05-27 1998-10-14 Sandoz Ltd Macrolide formulations
GB9601120D0 (en) 1996-01-19 1996-03-20 Sandoz Ltd Organic compounds
GB9606452D0 (en) 1996-03-27 1996-06-05 Sandoz Ltd Organic compounds
PT956034E (pt) * 1996-07-30 2002-12-31 Novartis Ag Composicoes farmaceuticas para o tratamento da rejeicao de transplantes estados inflamatorios ou auto-imunes compreendendo ciclosporina a e 40-o-(2-hidroxietil)-rapamicina
DE60044717D1 (de) * 1999-05-10 2010-09-02 Paolo Brenner Kombination von immunsuppressiven substanzen zur behandlung oder vorbeugung von transplantat abstossungen

Similar Documents

Publication Publication Date Title
JP2004210767A5 (https=)
NL1025404A1 (nl) Pyrazolo-triazine verbindingen en gebruik daarvan.
JP2003286379A5 (https=)
DK1697378T3 (da) Indoler, 1H-indazoler, 1,2-benzisoxazoler og 1,2-benzisothiazoler og fremstilling og anvendelser deraf
FI20030261A0 (fi) Iskulaite
DE602004029054D1 (de) Röntgenbeugungs-/-spektralvorrichtung vom energiedispersionstyp
DE60203537D1 (de) 5ht1-rezeptoragonist enthaltendes arzneimittel
NO20053947D0 (no) Forbedrede antitumorale behandlinger.
ITRM20030363A0 (it) Composizioni comprendenti la 3, 5diiodotironina e uso farmaceutico diesse.
JP2005532458A5 (https=)
NO20054034D0 (no) Fremgangsmate for behandling av hypotyroidisme.
RU2003120857A (ru) Адаптогенное средство
RU2002107007A (ru) Туберкулостатическое средство
RU2004132147A (ru) Адаптоген
ITRM20020470A0 (it) Lavatoio.
RU2000116332A (ru) Антгельминтное средство
JP2005082569A5 (https=)
ITTO20020476A1 (it) Composti pironici e loro utilizzo.
SE0202665D0 (sv) The W/F/T Sense ½
ES1056353Y (es) Taburete automontable.
ES1050769Y (es) Galleta perfeccionada.
ES1055804Y (es) Cajon flamenco perfeccionado.
ES1048873Y (es) Descapsulador perfeccionado.
ES1050018Y (es) Macetero perfeccionado.
ES1050297Y (es) Microfono perfeccionado.